Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2025-10-23
Sir, congratulations on your super delivery, consistent delivery for the last many quarters now. We recently shared some observations from the U.S. FDA for one of the company . Does that add to more tailwinds for us on the ARV side, which is already delivering strong numbers -- so there were U.S. FDA observations on Hetero plans, have you seen any incremental requests or inquiries on the ARV business in terms of products?
Okay. And secondly, sir, last question on margins, which has been very strong. Is there a scope of operating leverage kicks in margins to incrementally get better in the next 12 to 24 months for us?